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One of the events that is most vital to organ and organism
function is that of a hormone acting upon a cell to evoke a
physiological response. The hormone evoking the cellular re-
sponse is the "first messenger". The activation of a cellular
response, however, involves "secondary messengers" that are
generated in the cell as a result of hormone—receptor cell
interaction and that are crucial to the expression of hormone
action. The two most well—studied secondary messenger sys-
tems in hormone physiology are cyclic adenosine monophos-
phate (cAMP) and calcium. In this present chapter we will
describe the biochemical mechanisms in which vasopressin
interacts with its Vl and V2 receptors generating, in specific
cells, cAMP and/or calcium as second messengers. We will
focus on two cell culture models that have been utilized to
identify vasopressin signaling: 1) the LLC-PK1 cell which
contains the V2 receptor and 2) the glomerular mesangial cell
which contains the Vl receptor.
Vasopressin receptor (V2).adenylate cyclase interactions
The antidiuretic action of vasopressin is mediated by the
sequential steps of vasopressin binding to its cell surface
receptor, followed by the receptor—mediated stimulation of
adenylate cyclase. During the last decade it has become clear
that adenylate cyclase is part of a complex regulatory system,
consisting of at least three subunits for hormonal activation
[1—3]. These subunits, receptor (R), guanine nucleotide regula-
tory protein (G), and catalytic unit (C) have been characterized
by their individual biological properties using a variety of
techniques [2, 4]. The 0 subunit in turn consists of two major
subunits, termed a and /3, with molecular weights of (45 to 52)
x l0 and 35 x l0— respectively [4, 5]. A fundamental
question is how the individual subunits are structured in the
membrane before and after exposure to activating ligands [6]. In
this regard several possible models for the sequence of subunit
interactions involved in the activation of adenylate cyclase have
been proposed [7, 8]. Depending on the critical step involved in
the formation of the active enzyme species, these mechanisms
can be classified as associative or dissociative reactions. For
associative mechanisms, the hormone induces association of
subunits to form an active enzyme, and for dissociative mech-
anisms the hormone disaggregates subunits into active en-
zymes. In order to define the mechanism of adenylate cyclase
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activation by vasopressin, we turned to approaches that could
be applied to intact cells, thus avoiding possible disruption of
subunit assembly which accompanies solubilization and purifi-
cation techniques. The model system utilized was the cultured
pig kidney epithelial cell line, LLC-PK1, in which the vasopres-
sin V2 receptor is capable of stimulating cAMP production in
intact cells and in isolated membranes.
Binding of tritiated vasopressin in intact LLC-PK1 cells
The techniques used for establishing LLC-PK1 monolayer
cell cultures and the measurement of vasopressin binding and
cAMP accumulation have been previously described [9—13].
The basic characteristics of the vasopressin V2 receptor re-
ported in these studies were similar to those found in rat and
bovine renal membranes [10, 121. However, it was possible to
observe the regulation of receptor properties by hormone and
by other effectors in intact cells. Scatchard analysis of the
binding of tritiated lysine vasopressin to its receptor in LLC-
PK1 cells revealed a concave upward relation of bound/free
versus bound hormone [10]. One potential explanation for such
a concave upward plot is the occurrence of negatively cooper-
ative site—site interactions among receptors [14]. Studies of
hormonal dissociation have shown that true negative cooper-
ativity is not likely in this system. Rather, a number of
experimental maneuvers indicated that the concave upward
equilibrium Scatchard plot observed for the vasopressin V2
receptor in intact LLC-PK1 monolayers was most consistent
with the presence of interdependent states of the receptor of
varying hormone binding affinity [10, 12]. Furthermore, the
transition from a complex concave upward to a linear Scatchard
plot was observed with various manipulations of the cell,
including cell suspension and exposure to hypertonic incuba-
tion media [10, 12]. These data led us to the conclusion that a
complete understanding of the vasopressin receptor—adenylate
cyclase interactions could not be achieved from hormone
binding studies alone. Indeed, as will be demonstrated below,
without a full definition of the nature of the interaction between
the hormone receptor complex and other subunits of the
adenylate cyclase system, defining the model for hormone
action based on a description of nonlinear and/or linear
Scatchard plots is impossible. For this reason, we turned to the
technique of target analysis by radiation inactivation and ap-
plied it to intact, cultured cell monolayers to characterize the
sequence of subunit interactions involved in activation of
adenylate cyclase by vasopressin.
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The principles of radiation inactivation
When ionizing radiation is applied to an enzyme of interest,
loss of activity occurs as a function of the number of molecules
escaping destruction [15]. The probability of a molecule escap-
ing destruction in turn is a function of its molecular weight and
is given by a Poisson distribution, such that the logarithm (In) of
fractional activity surviving radiation is linearly related to
radiation dose. When this technique has been applied to a large
series of enzymes of known molecular weight (m), m was
related to the D0 dose by the relation:
640m=—
where D0 is the radiation dose in Mrad which reduced enzyme
activity by 37% (lIe) of its initial value and where m is
expressed in kDa. The majority of enzyme systems studied
have given single exponential inactivation curves with excellent
agreement between molecular weight determined by radiation
inactivation and by classical biochemical techniques [15].
In contrast, target analysis of adenylate cyclase has yielded
complex nonlinear ln(activity) versus dose relations which have
presented problems in interpretation [16, 17]. For this reason
we developed a systematic approach to interpret nonlinear
ln(activity) versus dose relations in terms of the interaction of
multimeric subunits of enzymes and then applied these methods
to vasopressin—sensitive adenylate cyclase [18—20]. It was ap-
parent that dramatic transitions of inactivation curve shape
were predicted for enzyme activation models associated with
disaggregation of relatively inactive multimers into active mo-
nomeric subunits. The nature of this transition depended upon
specification of radiation inactivation assumptions, namely: 1)
presence or absence of energy transfer; 2) multi-hit require-
ments for inactivation; and 3) equilibration of enzyme species
following radiation. The detailed curve shapes depended also
upon subunit molecular weights, multimer size, and relative
activity of multimer and monomer. For a fully equilibrated
system with no energy transfer, Figure 1 shows the ln(activity)
versus dose relation which is predicted to occur with activation
of the dissociative system,
AB< K (2)
in which all the activity resides in B* and in which the molecular
weights of A and B are nearly equal, A concave downward
ln(activity) versus dose relation is predicted for low K (disso-
ciation constant) values typical of a basal state of the enzyme,
with transition to a linear ln(activity) versus dose relation for
high K (full enzyme activation). At high enough radiation dose
and at high K, only the fully dissociated active B* subunit is
probed and the inactivation curve becomes linear with a slope
corresponding to the molecular weight of B. In contrast, for an
associative reaction in which inactive subunits A and B com-
bine to form the active multimer, AB, curve shape transition
would be opposite that seen in Figure 1. In general, for a
complex multistep activation process, the pattern of curve
shape transition (associative vs. dissociative) will be deter-
mined by the step leading to the formation of the species whose
concentration limits final activity [18—20].
Radiation inactivation of vasopressin—sensitive adenylate
cyclase in intact LLC-PK1 cells
We applied the technique of radiation inactivation to distin-
guish an associative versus dissociative mechanism for activa-
tion of adenylate cyclase by vasopressin [19, 20]. A pattern of
curve shape transition consistent with a dissociative activation
mechanism was clearly obtained (Figs. 2 and 3). In the basal
state a concave downward inactivation curve was observed
with a limiting slope corresponding to a molecular weight of
approximately 180 kDa (Fig. 2). In contrast the addition of
vasopressin (Fig. 3A), guanine nucleotides (Fig. 3B), or
forskolin (Fig. 3C) resulted in curve shape transition to a linear
ln(activity) versus dose relation with a slope corresponding to a
molecular weight similar to that observed at basal activity (that
is, 180 kDa). Based on the theory outlined in the previous
section, this value was shown to correspond to the molecular
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Fig. 1. Radiation inactivation of the dissociative reaction AB A + B
with B the active species. The molecular weights of A and B are equal.
Complete equilibration is allowed after radiation exposure. K is a
dissociation constant; increasing K results in an increase in the quantity
of active B. Reprinted with permission from [191.
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Fig. 2. Activity—dose relation for the radiation inactivation of basal
adenylate cyclase in LLC-PK1 cells. Reprinted with permission from
[20].
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A Table 1. Criteria for adenylate cyclase activation mechanism
1. Non-linear coupling of receptor occupancy to enzyme activation
2. Non-linear Scatchard for equilibrium hormone binding under
appropriate conditions of receptor—enzyme stoichiometry
3. GTP lowers hormone binding affinity
4. Molecular weight of active species: approximately 180 kDa
5. Shallow initial slope and prominent downward concavity for
basal radiation inactivation curve
>.
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Fig. 4. csf3 Cyclic dissociation model for adenylate cyclase activation.
Abbreviations are: H, hormone; R, receptor; a, /3, subunits of guanine
nucleotide—regulatory protein; C, catalytic unit; GTP and GDP,
guanosine triphosphate and diphosphate, respectively; P3, inorganic
phosphate; D and T subscripts denote GTP-and GDP-associated states
c ofa, respectively. KHR, K'HR, Kc, and K are equilibrium dissociation
constants and k0, k, k'0, k', k1, k2 are kinetic constants. Reprinted
with permission from [20].
weight of the species whose interaction limits final activity. The
molecular weight of the catalytic unit (C), which clearly must be
part of the final active species, has been estimated at 120 to 150
kDa [21—23]. Since the target size is greater than the estimates
for C alone, constituents of the final active species include C
plus another subunit component.
The above target analysis data were combined with known
biochemical characteristics of the vasopressin adenylate cy-
clase system (Table 1) to formulate a unique pattern for the
interaction of the adenylate cyclase subunits (Fig. 4). It should
be noted that the biochemical criteria, 1 to 3, listed in Table 1
are general characteristics of a number of hormone—receptor
adenylate cyclase systems, and not limited to the vasopressin
activation of this enzyme. When the criteria in Table 1 were
utilized to evaluate potential mechanisms for adenylate cyclase
activation [19, 201, only the model illustrated in Figure 4 was
able to satisfy all criteria. According to this model, hormone (H)
interacts with its free receptor to form an HR complex which in
turn can interact with either aGDP or aGTP. The aGDP subunit is
the high affinity subunit for HR binding, and GTP lowers the
affinity of hormonal binding during the formation of HR aGTP.
The multiple interdependent binding sites for hormone account
for the presence of a nonlinear Scatchard plot which, interest-
ingly, could be converted to a linear Scatchard plot depending
on the relative stoichiometry of R and a and the individual
binding affinities. As noted above, such a transition in Scat-
chard plots for vasopressin binding has been observed [10, 12].
Dose, Mrad
H+R
HR
I K'
C
Dose, Mrad
8
Dose, Mrad
Fig. 3. Activity—dose relation for the radiation inactivation of adenylate
cyclase stimulated by A: 2jM vasopressin; B: 10 /SM guanylyl
imidodiphosphate; and C: 100 Mforskolin. Reprinted with permission
from [20].
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Table 2. Predictions from the model of vasopressin activation of
adenylate cyclase
1 Hormone—receptor complex interacts with dissociated a subunit
2. GDP-GTP interconversion takes place on the dissociated a
subunit
3. Effect of hormone is to accelerate GTP addition on a
4. af3 dissociation occurs as part of the activation process in the
intact membrane
The coupling ratio of receptor occupancy to enzyme activation
will be a function of the lifetime of activated C* compared to the
rate of unbinding of hormone. If C* is long lived, non-linear
coupling will occur.
Finally the mechanism shown in Figure 4 satisfies the details
of the radiation inactivation data. The species whose concen-
tration limits overall activity is aGTPC. This corresponds to the
target size of 180 kDa (a = 45 kDa; C = 120 to 150 kDa)
obtained for the active species for radiation inactivation. A
prominent degree of initial downward concavity at low radia-
tion dose is predicted for basal enzyme activity, as was ob-
served (Fig. 2). This arises because GDP-GTP interconversion
limits the amount of aGTp available for association with C in the
steady state, so that the initial curve shape will reflect predom-
inantly the molecular weight of a and therefore will appear
shallow. At high radiation dose, which is conceptually equiv-
alent to a large dilution of the components, af3 will be predom-
inantly in the dissociated state, resulting in transition toward a
linear plot with composite target size of aC. We have generated
the expected ln(activity) versus dose relations for this model,
based upon an explicit delineation of the equations which define
the mechanism, and confirmed this curve shape for basal
activity and the linear transition with hormone and other
activators [19, 20]. It is equally important to note that a number
of other plausible models previously suggested in the literature
as mechanisms of activation of adenylate cyclase can be ex-
cluded on the basis of their inability to satisfy all the criteria in
Table 1. The models eliminated included those in which a/3
dissociation was assigned as the hormone sensitive step, as well
as models in which there was precoupling of either R or C with
the a/3 subunits [19, 20].
The model in Figure 4 yields a number of testable predictions
for adenylate cyclase activation by vasopressin listed in Table
2. These features can now be evaluated by biochemical means
in the intact membrane.
Use of the adenylate cyclase model to understand the
antidiuretic action of vasopressin
Hormones, drugs, and the hypertonic environment of the
renal medulla are known to modulate the vasopressin stimula-
tion of adenylate cyclase. Recent studies have allowed us to
define the mechanism of action of a variety of agents on the
basis of their alteration of vasopressin—adenylate cyclase
subunit interactions as illustrated in Figure 4.
Incubation with high concentrations of vasopressin for a few
minutes is known to cause a "desensitization" of the vasopres-
sin adenylate cyclase—response [11]. This actue desensitization
is not associated with loss of receptor number, but rather is the
result of an apparent uncoupling between the hormone receptor
complex and the adenylate cyclase system. This phenomena is
a common one for many hormones and it is one of the important
ways that cells can rapidly regulate their responses to a hor-
mone [24]. We have recently been able to demonstrate that
desensitization to vasopressin in LLC-PK1 cells is consistent
with a decrease in the rate of the reaction defined by the rate
constant, k'G, in Figure 4 (unpublished observations). The
implications of this conclusion are that some biochemical
modification of either the vasopressin receptor or the a subunit
results in a blunted ability of HRXGDP to form the HRaGTP
complex. Recent observations by Sibley and Lefkowitz [24]
have demonstrated that the f3-adrenergic receptor can be
phosphorylated by a variety of protein kinases, including pro-
tein kinase A and protein kinase C, resulting in the desensiti-
zation of the /3-adrenergic response. A similar phenomena may
occur for the vasopressin receptor. Indeed, early evidence from
our laboratory [121 suggested that ATP had a facilitory effect on
the desensitization phenomena, possibly related to a phospho-
rylation event. The phosphorylation of the vasopressin receptor
could be associated with an altered hormone—binding affinity, as
has been observed for the desensitized state [10, 12 and
unpublished observations], as well as inhibit the ability of the
HR complex to interact with the a subunit. Full definition of
this process will require purification of the appropriate
subunits.
Since vasopressin can exert its action upon its receptor and
adenylate cyclase in a hypertonic environment, it is not surpris-
ing that hypertonic sodium chloride has been found to have pro-
found effects on the ability of vasopressin to stimulate cAMP.
When hypertonic sodium chloride is added to the incubation
media with kidney medullary membranes, a several—fold in-
crease in vasopressin—stimulated adenylate cyclase activity is
observed [25]. Hypertonic sodium chloride can similarly en-
hance the vasopressin response in the cultured LLC-PK1 cells,
and, most interestingly, can prevent the desensitization induced
by vasopressin described above [10—12]. The regulation of
vasopressin—sensitive adenylate cyclase by hypertonic sodium
chloride in vitro is consistent with a similar effect of hypertonic-
ity observed in the Brattleboro rat with hypothalamic diabetes
insipidus (DI) in vivo. In these rats the sensitivity of the
medullo-papillary adenylate cyclase to vasopressin is reduced
[26, 27]. Chronic administration of physiological concentrations
of vasopressin in vivo induced a 30% increase in the respon-
siveness of the enzyme to vasopressin in vitro [27]. These data
are consistent with the hypothesis that vasopressin recep-
tor—adenylate cyclase interactions can be controlled by the
chemical composition of the renomedullary interstitial fluid, as
in the LLC-PK1 cells. The inability of the DI rats to maximally
concentrate urine, presumably as a consequence of minimal
stimulation of adenylate cyclase, may be due to the subnormal
solute concentration prevailing in the renal medulla. With
prolonged treatment of the DI rats with vasopressin, which
gradually increases medullary osmolality, there is a restoration
of the concentrating ability of the kidney to normal [28].
In order to define the mechanism by which hypertonic
sodium chloride stimulates adenylate cyclase, we conducted
target analysis studies with radiation inactivation as described
above [29]. Interestingly, activation of adenylate cyclase by
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sodium chloride is not associated with a curve shape transition
from downward concavity to linear as was observed with the
other activators of the enzyme (Figs. 2 and 3). In addition, the
combination of vasopressin plus hypertonic sodium chloride
was not capable of fully linearizing the radiation inactivation
curve shape. We have interpreted these data to mean that there
is little if any dissociation of af3 in the presence of sodium
chloride despite activation of the enzyme. Hypertonic sodium
chloride may well provide a means by which the intact a/3
complex is capable of undergoing GDP-GTP transition in the
presence of hormone and facilitating coupling to the catalytic
unit and activation of the enzyme. It may be that this altered
state of subunit association can prevent desensitization and/or
facilitate the association of a "desensitized" vasopressin recep-
tor with the intact a$ complex. These data provide a potential
molecular mechanism for the physiological modulation of the
vasopressin—adenylate cyclase interaction by hypertonic so-
dium chloride. This model of activation by sodium chloride may
prove to be a key determinant of the maximal rate and duration
of cAMP signaling induced by vasopressin in the renal medulla.
Interaction of calcium with the cAMP signal
It has become clear in the least several years that the majority
of hormone—stimulated transport events involve interactions
between the two major messenger systems, cAMP and Ca2.
These interactions can occur at the level of synthesis of the
messages themselves, or at a variety of steps leading to the
physiologic response of the hormone. In this section we will
describe the mechanisms by which Ca2 — calmodulin can alter
the vasopressin—stimulated cAMP signal, and cite physiological
examples in which Ca2 may be playing such a modulatory role.
Calmodulin (CaM) can have a significant effect on the syn-
thesis and degradation of cAMP [301. However, while CaM and
adenylate cyclase are ubiquitous in mammalian cells, CaM
regulation of basal adenylate—cyclase activity has been limited
to a few tissues, including those from the brain, pancreas, and
adrenal glands [31—331. We have described the activation of
vasopressin—sensitive adenylate cyclase by CaM [13]. Previous
studies with oxytocin in adenylate cyclase preparations from
the frog bladder [34] and with vasopressin in similar prepara-
tions from the kidney medulla [351 had demonstrated a biphasic
adenylate cyclase response with increasing Ca2 concentra-
tions. Ca2 in the micromolar range was required for activation;
further increases in Ca2 resulted in inhibition. At the time of
those studies, the existence of CaM was unknown.
Using the LLC-PK1 cell line we were able to demonstrate
that the characteristics of CaM stimulation of vasopres-
sin—sensitive adenylate cyclase were similar to those described
for other enzymes [13], specifically: 1) activation required
micromolar quantities of free Ca2; 2) maximum enzyme rates
were altered, but the Km for hormone activation was not; 3)
activity was inhibitable by trifluoperazine; 4) activation was
dependent on the Mg2 concentration; and 5) CaM exerted a
biphasic effect on vasopressin—sensitive adenylate cyclase, with
activation occurring at low Ca2 and inhibition at high Ca2
concentrations.
The mechanism by which CaM regulates adenylate cyclase
has not been firmly established, although it seems most likely
that it stimulates the catalytic unit directly [301. The fact that
CaM stimulates adenylate cyclase from only a limited number
of tissues suggests that these enzymes are distinct from adenyl-
ate cyclases that are not regulated by CaM.
The physiologic significance of the CaM regulation of
vasopressin—sensitive adenylate cyclase also remains to be
demonstrated. Such a regulatory system however can offer a
potentially unifying hypothesis for vasopressin—stimulated wa-
ter flow in the mammalian kidney and amphibian bladder.
Several years ago, Petersen and Edelman [36] demonstrated
that high Ca2 concentrations in the serosal bathing medium of
the toad urinary bladder selectively inhibited the hydroosmotic
effect of vasopressin without altering the natriuretic response of
the hormone. This inhibition of Ca2 was overcome by
exogeneous cAMP. These observations led the authors to
propose that vasopressin activates two adenylate cyclases, one
of which is Ca2-sensitive and coupled to the regulation of
osmotic water flow. This hypothesis is consistent with the
observation that large increases in extracellular Ca2 blunt
vasopressin stimulation of cAMP in toad bladder cells [37].
Studies have demonstrated that prostaglandins [37, 38],
verapamil [39], general anesthetics [40, 41], and a-adrenergic
agents [37, 421 selectively inhibit vasopressin—stimulated water
flow in the toad bladder by decreasing the ability of the
hormone to enhance cAMP production. In the mammalian
kidney, it has been suggested that prostaglandins and verapamil
inhibit vasopressin—stimulated water flow by a common mech-
anism [43]. It is thus possible that all of these agents share an
ability to inhibit Ca2-sensitive adenylate cyclase. For CaM-
sensitive enzymes studied to date [30, 44], a small increase in
the Ca2 concentration results in a Ca2-CaM complex that is
capable of activating the enzyme. Our data in the LLC-PK1
cells would suggest that an inhibitor might act on the vasopres-
sin—sensitive enzyme by: 1) preventing the necessary increment
in the Ca2 concentration; 2) stimulating a large increase in the
Ca2-CaM complex (the "biphasic" response); 3) preventing
the interaction of the Ca2-CaM complex with the enzyme; and
4) altering the Mg2 concentration. It is of interest that several
substances that act as Ca2 antagonists, such as anesthetics and
verapamil, have been shown to inhibit Ca2-CaM in much the
same manner as trifluoperazine [45, 46]. It is thus possible that
the observed effects of prostaglandins, verapamil, and anesthet-
ics on the physiologic action of vasopressin are mediated
through the effects of these agents on the Ca2-CaM system.
Once cAMP is generated inside cells by adenylate cyclase, it
is degraded by a variety of phosphodiesterases, at least one of
which is activated by Ca2-CaM [30]. In contrast to Ca2-CaM-
stimulated adenylate cyclase discussed above, Ca2tCaMsen
sitive phosphodiesterase is a ubiquitous enzyme found in all
mammalian cells. The observation that CaM stimulates the
activities of both adenylate cyclase and phosphodiesterase may
appear paradoxic. However, the sensitivity of adenylate cy-
clase and phosphodiesterase to Ca2 is different [47]. Adenylate
cyclase is activated by a lower concentration of Ca2 and, at a
concentration of Ca2 that activates phosphodiesterase, adenyl-
ate cyclase is already inhibited. Thus, an increase in cellular
free Ca2 may cause a sequential activation of adenylate
cyclase and phosphodiesterase, resulting in a transient accumu-
lation of cAMP.
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Vasopressin receptor V1 calcium—phospholipid interactions
Vasopressin receptors have been divided into two groups, V1
and V2, based primarily on functional characteristics. While the
V2 receptor, as discussed above, is coupled to adenylate
cyclase the V1 receptor is not. Interactions between vasopres-
sin and cells with V1 receptors involve calcium as a second
messenger system. V1 receptors are present in three sites in the
kidney: the glomerular mesangial cell, vascular smooth muscle
cell, and the renomedullary interstitial cell. We will discuss the
characteristics of the vasopressin—V1 interactions in the mesan-
gial and renomedullary interstitial cell.
Glomerular mesangial cell
Vasopressin induces contraction [48] and prostaglandin syn-
thesis [49, 50] in cultured glomerular mesangial cells. It has
been suggested that the glomerular mesangial cell is the primary
regulator of glomerular capillary surface area, and therefore, Kf
[51]. The contractile response to vasopressin may be responsi-
ble for the alteration in Kf observed with vasopressin in the
intact glomerulus. The prostaglandin synthesis in turn has been
postulated to modulate the contractile response on the mesan-
gial cell itself, and both vasopressin—induced contraction and
prostaglandin (PGE2) synthesis are blocked by a V1 receptor
antagonist [49, 521, thus implicating the V1 receptor in media-
tion of these events. Bonventre et al [53], using both quin2
and fura-2 as intracellular fluorescent Ca2 indicators, have
demonstrated that vasopressin increases cytosolic free cal-
cium concentration ([Ca2]f) in the cultured mesangial cell.
This response is blocked by the V1 receptor antagonist,
(CH2)5Tyr(ME)VD AVP. Basal levels of [Ca2] were approxi-
mately 80 to lO5nM. Vasopressin produced approximately an
eightfold increase in [Ca2]f within seconds of addition of the
hormone. This was followed by a rapid fall in [Ca2] with levels
returning to approximately 50% above baseline within one
minute of addition of vasopressin (Fig. 5). The increase in
[Ca2]f was due in large part to release of Ca2 from intracel-
lular storage sites since the [Ca2] response was observed even
when extracellular Ca2 concentration was reduced to levels
lower than 100 nM. There may, however, be an additional
contribution to the [Ca2] rise due to entry of extracellular
Ca2t Reduction of extracellular calcium concentration to lev-
els below 100 nM results in reduction in the initial rise of [Ca2]f
and more rapid return of mean [Ca2]f to baseline. The time
response of [Ca2]f to vasopressin depicted in Figure 5 does not
necessarily reflect the time response in any individual cell. The
response presented represents a mean response of a large
number of cells that may not be activated in synchrony. It has
been shown, for example, in single hepatocytes that vasopres-
sin stimulates repetitive transient rises in [Ca2]f [54].
In other tissues, such as liver [55], vascular smooth muscle
cells [56] and platelets [57], vasopressin results in a rapid
phosphodiesterase—mediated hydrolysis of phosphatidylinosi-
tol-4-5-bisphosphate with the production of myo-inositol-1 ,4,5-
trisphosphate (1P3). Troyer et al [52] have demonstrated that
vasopressin also increases metabolism of polyphospho-
inositides in cultured mesangial cells. Since 1P3 releases Ca2
from nonmitochondrial stores in mesangial cells (Bonventre and
Cheung, unpublished observations) it is likely that 1P3 serves as
an intracellular second messenger for hormone—induced Ca2
0L I
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Fig. 5. Effect of lOOnM arginine vasopressin (A VP) on cytosolic free
[Ca2] ([Ca2 J) in cultured mesangial cells. [Ca2]f was measured by
incorporation of a Ca2 sensitive fluorescent dye, fura-2, into the cell.
The AVP-treated cells are compared with time matched control cells.
[Ca2]f increased by approximately eight-fold within seconds of addi-
tion of AVP. Within 60 seconds after addition of hormone [Ca2]r
returned to a level approximately 50% higher than control. At each time
point [Ca2ir in AVP-treated cells (j N = 17) was statiscally higher
than the control value (, N = 8) (P < .025). Reprinted with permission
from 1531.
release. A working scheme for the elevation of [Ca2]f after
hormone-V1 receptor interactions, along with the varied cellu-
lar responses to this increase in [Ca2], identified in various cell
types, is presented in Figure 6. From work done in other cells,
it has become apparent that the scheme depicted in Figure 6, for
the Ca2-polyphosphoinositide second messenger system, is an
oversimplification [58]. Inositol [l,3,4,5]P4(1P4) is formed as
rapidly as inositol (l,4,5)P3 (1P3) in some stimulated cells and
1P3 may be metabolized via 1P4. 1P5 and 1P6 have also been
isolated from mammalian cells [58]. It has also been established
that 1,2 cyclic derivatives of inositol phosphates can be gener-
ated from phosphatidylinositol-4,5-bisphosphate and phosphati-
dylinositol-4-monophosphate by phospholipase C [59]. Each of
these compounds may have its own, as yet undefined, action in
the cell.
The increase in [Ca2]f observed with vasopressin is likely
related to the vasopressin—induced contraction observed in the
mesangial cell. By analogy to other contractile cells such as
smooth muscle, an increase in [Ca2]f with an associated
increase in calmodulin binding likely leads to enhance myosin
light—chain phosphorylation.
Prostaglandin synthesis is also a result of vasopressin—V1
receptor interactions. Diacylglycerol generated by phospholi-
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Protein kinase C
activity
1 Protein kinases
a) Myosin light chain kinase
b) Phosphorylase kinase
c) Ca'-calmodulin protein kinase
2 Cyclic nucleotide phosphodiesterase
3 Adenylate cyclase
4 Phospholipase A2
5 Microtubule disassembly
6 NAD kinase
7 Ca2-ATPase
Fig. 6. Simpljfied scheme for the elevation of cytosolic free [Ca2] after
vasopressin-V1 receptor interaction, along with the varied cellular
responses activated by the system in many cell types. The Ca2 signal
may express its activity through a number of binding proteins including
calmodulin, gelsolin or villin, troponin C or protein kinase C. As
indicated by the dashed line, an elevation in cytosolic free [Ca2] is not
necessary for protein kinase C activation in the presence of
diacylglycerol (1,2 DG) and phospholipids but may potentiate this
kinase activity. The example of Ca2-dependent processes is not all
inclusive. Abbreviations are: PhI, phosphatidylinositol; PI4P, phos-
phatidylinositol-4-phosphate; P14,5P2, phosphatidylinositol-4,5-bis-
phosphate; PhA, phosphatidic acid. Modified from: Ausiello and
Bonventre, Semin. Nephrology 4:134—143, 1984
pase C can be sequentially hydrolyzed by diglyceride and
monoglyceride lipases resulting in arachidonic acid release and
subsequent prostanoid generation (60). The increased [Ca2]
associated with vasopressin activation can also explain the
enhanced prostaglandin synthesis via activation of Ca2-de-
pendent phospholipase A2 liberating arachidonic acid from
various phospholipids. Even when extracellular Ca2 concen-
tration is reduced to below lOOnM there is a large increase in
PGE2 synthesis after vasopressin treatment (50), supporting the
concept that activation of cellular phospholipases is not depen-
dent on entry of Ca2 from the extracellular milieu.
In contrast to the marked increase in [Ca2] observed with
vasopressin there was no increase in adenylate cyclase activity
in the mesangial cell with this hormone. Furthermore [Ca2]f
was not altered by activation of adenylate cyclase with
isoproterenol or direct addition of 1 m dibutyryl cAMP (53),
nor was the vasopressin-induced increase in [Ca2]f affected by
isoproterenol or dibutyryl-cAMP. The action of isoproterenol
to prevent vasopressin-induced contraction in mesangial cells
(61) is, therefore, likely due to a dissociation of the change in
[Ca2]f from force generation. This might be explained by an
inhibitory effect of cAMP on the Ca2-calmodulin induced
phosphorylation of myosin light chains (53).
Medullary slices and the renomedullary interstitial cell
Vasopressin stimulates PGE2 production in renomedullary
interstitial cells [62] and possibly, to a diminished extent, in the
medullary collecting duct [63], but does no appear to signifi-
cantly alter prostaglandin synthesis in other medullary cells
[64]. The increase in prostaglandin synthesis in the interstitial
cell is due to a stimulation of cellular phospholipase activity and
is not evoked by the V2 receptor agonist, dDAVP [65, 66]. It is
likely that vasopressin induces an increase in [Ca2]f in the
renomedullary interstitial cell analogous to the vasopressin
effect on mesangial cells. [Ca2if has never been measured in
this cell; however, the stimulation of prostaglandin synthesis in
the cell is Ca2 dependent in that reduction of extracellular Ca
results in reduction in the rate of secretion of PGE2 [67]. The
calcium channel—blocking agent, verapamil, and the relatively
non-specific Ca2-calmodulin inhibitor, trifluoperazine, also
inhibited PGE2 production implicating Ca2 as an important
factor in the vasopressin—induced response in the cell [67]. The
role of the phosphoinositide system in the Ca2 or prostaglandin
response has not been evaluated.
Studies using medullary tissue slices also implicate Ca2 and
calmodulin in the regulation of prostaglandin production in the
renal medulla. In kidney medullary slices it has been found that
Ca2 ionophore (A23 187)-induced stimulation of prostaglandin
production is abolished by reduction of extracellular Ca2
concentration [68—72]. Furthermore, putative inhibitors of
calmodulin, trifluoperazine and W-7 (N-6-aminohexyl-5-chloro-
1 naphthalene sulfonamide hydrochloride) suppress vasopres-
sin in A23 187-induced prostaglandin production [68—72].
Implications of vasopressin—Vj receptor interactions for
urinary concentration
The interactions between vasopressin and cells possessing
the V1 receptor are complex and offer many potential implica-
tions for urinary concentration. The prostaglandins that form as
a result of V1 receptor activation can alter urinary concentrating
ability by: 1) changing medullary blood flow; 2) altering solute
transport into the medullary interstitium; or 3) altering the
hydrosmotic effect of vasopressin. Vasodilatory prostanoids
likely increase medullary blood flow which may enhance med-
ullary solute washout, thereby reducing concentrating ability.
Sodium transport in the medullary collecting duct is inhibited
by PGE2 [73]. Furthermore, PGE2 antagonizes the action of
vasopressin on the thick ascending limb as reflected by de-
creased cAMP production as well as chloride transport [74, 75].
Medullary NaCl concentration increases when prostaglandin
synthesis is inhibited [76]. Although prostaglandins have little
effect on basal water permeability in the collecting duct, they
markedly impair the increased water permeability seen with
vasopressin in the cortical collecting duct and the toad bladder.
Therefore in many cases prostaglandins serve as antagonists of
vasopressin action. By contrast it has been demonstrated that
vasoconstrictor cyclo-oxygenase products such as thrombox-
ane and cyclic endoperoxide analogs [77] can potentiate the
effect of vasopressin in nonmammalian tissues; however, the
relevance of these findings to the mammal remain unclear. In
summary, vasopressin—V1 receptor interactions are important
to the function of the renal medulla. The net effect of
prostaglandin synthesis is to decrease concentrating ability as
demonstrated by the observation that blockage of prostaglandin
synthesis with indomethacin results in an increase in urinary
concentration and papillary solute content [75, 78].
tCa2-calmodulin
activates
1 Microfilament disassembly
Igelsolin or villin)
2 Muscle contraction
)troponin Cl
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Conclusion
The ability of vasopressin to induce antidiuresis is the result
of its combined effects on V1 and V2 receptors in multiple renal
cell types. The complex interactions of the V2 receptor with the
adenylate cyclase subunits have been described at the molecu-
lar level and help to provide an understanding of the regulation
of this enzyme by hormone and other agents. The molecular
events involved in V1 receptor signaling are less well defined,
but the response is characterized by significant changes in
phospholipid metabolism and intracellular free [Ca2I. Our
expanding knowledge of vasopressin signalling will eventually
provide for the full molecular definition of vasopressin action.
Acknowledgments
We acknowledge the editoral and secretarial assistance of Joan
Carrick. This work was supported by USPHS Grants AM-19406,
AM-35124, and HL-31513, Ontario Heart Foundation Grant AN 106,
and a Kidney Foundation of Canada grant. K.L. Skorecki is a scholar
of the Canadian Heart Foundation.
Reprint requests to D.A. Ausiello, Renal Unit, Jackson 7, Massa-
chusetts General Hospital, Boston, Massachusetts 02114, USA.
References
1. RODBELL M: The role of hormone receptors and GTP-regulatory
proteins in membrane transduction. Nature 284:17—22, 1980
2. Ross EM, GILMAN AG: Biochemical properties of hormone—sensi-
tive adenylate cyclase. Ann Rev Biochem 49:533—564, 1980
3. STILES GL, CARON MG, LEFK0wITz RJ: /3-Adrenergic receptors:
Biochemical mechanisms of physiological regulation. Physiol Rev
64:661—743, 1984
4. SMIGEL MD, Ross EM, GILMAN AG: Role of the /3-adrenergic
receptor in the regulation of adenylate cyclase, in Cell Membranes
Methods and Reviews, (vol 2) edited by ELSON E, FRAZIER W,
GLA5ER L. New York, Plenum Press, p. 247—294, 1984
5. STERNwEIS PC, NORTHRUP JK, HAN5KI E, SCHLEIFER LS,
SMIGEL MD, GILMAN AG: Purification and properties of the
regulatory component (GIF) of adenylate cyclase. Adv Cyclic
Nucleotide Res 14:23—36, 1981
6. BIRNBAUMER L, IYENGAR R: Coupling of receptors to adenylate
cyclases, in Handbook of Experimental Pharmacology, (vol 58)
edited by NATHANSON JA, KEBABIAN JW. Berlin, Springer—
Verlag, p. 153—183, 1982
7. TOLKOVSKY AM, LEVITZKI A: Mode of coupling between the
/3-adrenergic receptor and adenylate cyclase in turkey erythro-
cytes. Biochemistry 17:3795—3810, 1978
8. TOLKOVSKY AM, LEVITZKI A: Theories and predictions of models
describing sequential interactions between the receptor, the GTP
regulatory unit, and the catalytic unit of hormone dependent
adenylate cyclases. J Cyclic Nucleotide Res 7:139—150, 1981
9. GOLDRING SR, DAYER JM, AUSIELLO DA, KRANE SM: A cell
strain cultured from procine kidney increases cyclic AMP content
upon exposure to calcitonin or vasopressin. Biochem Biophys. Res.
Commun 83:434—440, 1978
10. Roy C, AU5IELLO DA: Characterization of (8-lysine) vasopressin
binding sites on a pig kidney cell line (LLC-PK1). Evidence for
hormone-induced receptor transition. J Biol Chem 256:3415—3422,
1981
11. RoY C, HALL D, KARI5H M, AU5IELL0 DA: Relationship of
(8-lysine) vasopressin receptor transition to receptor functional
properties in a pig kidney cell line (LLC-PK1). J Biol Chem
256:3423—3427, 1981
12. Ro C, AU5IELL0 DA: Regulation of vasopressin binding to intact
cells. Ann NYAcad Sci 372:92—105, 1981
13. AU5IELL0 DA, HALL D: Regulation of vasopressin—sensitive ade-
nylate cyclase by calmodulin. J Biol Chem 256:9796—9798, 1981
14. DEMEYTS PD, BIANc0 AR, ROTH J: Site—site interactions among
insulin receptors. J Biol Chem 251:1877—1888, 1976
15. KEMPNER ES, SCHLEGEL W: Size determination of enzymes by
radiation inactivation. Anal Biochem 92:2—10, 1979
16. MARTIN BR, STEIN JM, KENNEDY EL, DOBER5KA CA, METCALFE
JC: Transient complexes. A new structural model for the activation
of adenylate cyclase by hormone receptors. Biochem J 184:
253—260, 1979
17. SCHLEGEL W, KEMPNER ES, RODBELL M: Activation of adenylate
cyclase in hepatic membranes involves interactions of the catalytic
unit with multimeric complexes of regulatory proteins. J Biol Chem
254:5168—5176, 1979
18. VERKMAN AS, SKORECKI KL, AU5IELL0 DA: Radiation inactiva-
tion of oligomeric enzyme systems: theoretical considerations.
Proc NatlAcad Sci USA 81:150—154, 1984
19. VERKMAN AS, SKORECKI KL, AU5IELLO DA: Radiation inactiva-
tion of multimeric enzymes: application to subunit interactions of
adenylate cyclase. Am J Physiol 250(Cell Physiol 19):C103—C 114,
1986
20. SKORECKI KL, VERKMAN AS, JUNG CY, AU5IELLO DA: Evidence
for vasopressin activation of adenylate cyclase by subunit dissocia-
tion. Am J Physiol 250(Cell Physiol.19):C115—C123, 1986
21. ANDREASEN TJ, HEIDEMAN W, ROSENBERG GB, STR0M5 DR:
Photoaffinity labeling of brain adenylate cyclase preparations with
azido[125lliodocalmodulin, Biochemistry 22:2757—2762, 1983
22. BENDER JC, WOLF LG, NEER EJ: Interaction of forskolin with
resolved adenylate cyclase components. Advances in Cyclic Nude-
otide and Protein Phosphorylation Research 17:101—109, 1984
23. PFEUFFER E, DREHER R-M, METZGER H, PFEUFFER T: Catalytic
unit of adenylate cyclase: Purification and identification by affinity
crosslinking. Proc Nat! Acad Sci USA, 82:3086—3090, 1985
24. SIBLEY DR, LEFKOWITZ RJ: Molecular mechanisms of receptor
desensitization using the /3-adrenergic receptor—coupled adenylate
cyclase system as a model. Nature 3 17:124-129, 1985
25. Ro C, LEBARS NC, JARD 5: Vasopressin—sensitive kidney adenyl-
ate cyclase. Differential effects of monovalent ions on stimulation
by fluoride, vasopressin and guanylyl 5'-imidodiphosphate. Eur J
Biochem 78:325—332, 1977
26. DOUSA TP, HUI YFS, BARNES LD: Renal medullary adenylate
cyclase in rats with hypothalamic diabetes insipidus. Endocrinol-
ogy 97:802—807, 1975
27. RAJERISON RM, BUTLEN D, JARD 5: Effects of in vivo treatment
with vasopressin and analogues on renal adenylate cyclase respon-
siveness to vasopressin stimulation in vitro. Endocrinology
101:1—12, 1977
28. HARRINGTON AR, VALTIN H: Impaired urinary concentration after
vasopressin and its gradual correction in hypothalamic diabetes
insipidus. J C/in Invest 47:502—510, 1968
29. VERKMAN AS, Au5IELL0 DA, JUNG CY, SKORECKI KL: Mecha-
nisms of non-hormonal activation of adenylate cyclase based on
target analysis. Biochemistry 25:4566—4572, 1986
30. MANALAN AS, KLEE CB: Calmodulin. Advances in Cyclic Nude-
otide and Protein Phosphorylation Research 18:227—278, 1984
31. BROSTROM CO, HUANG YC, BRECKENRIDGE BM, WOLFF DJ:
Identification of a calcium-binding protein as a calcium—dependent
regulator of brain adenylate cyclase. Proc NatI Acad Sci USA
72:64—68, 1975
32. VALVERDE I, VANDERMEERS A, ANJANEYULU R, MALAISSE WJ:
Calmodulin activation of adenylate cyclase in pancreatic islets.
Science 206:225—227, 1979
33. LEDONNE NC JR, COFFEE CJ: Evidence for calmodulin sensitive
adenylate cyclase in bovine adrenal medulla. Ann NY Acad Sci
356:402—403, 1980
34. BOCKAERT J, Roy C, JARD 5: Oxytocin—sensitive adenylate cyclase
in frog bladder epithelial cells: Role of calcium, nucleotides,and
other factors in hormonal stimulation. J Biol Chem 247:7073—7081,
1972
35. CAMBELL BJ, WOODWARD G, BORBERG V: Calcium—mediated
interactions between the antidiurectic hormone and renal plasma
membranes. J Biol Chem 247:6167—6175, 1972
36. PETERSEN MJ, EDELMAN IS: Calcium inhibition of the action of
vasopressin on the urinary bladder of the toad. J C/in Invest
43:583—594, 1964
37. OMACHI RS, ROBBIE DE, HANDLER JS, ORLOFF J: Effects of ADH
and other agents on cyclic AMP accumulation in toad bladder
Vasopressin signaling in kidney cells 529
epithelium. Am J Physiol 226:1152—1157, 1974
38. ORLOFF J, HANDLER JS, BERGSTROM S: Effect of prostaglandin
(PGE-1) on the permeability response of toad bladder to vasopres-
sin, theophylline and adenosine 3', 5'-monophosphate. Nature
205:397—398, 1965
39. HUMES HD, SIMMONS CF JR, BRENNER BM: Effect of verapamil
on the hydroosomotic response to antidiurectic hormone in toad
urinary bladder. Am J Physiol 239:F250—F257, 1980
40. LEVINE SD, LEVINE RD. WORTHINGTON RE, HAYS RM: Selective
inhibition of osmotic water flow by general anesthetics in toad
urinary bladder. J Clin Invest 58:980—988, 1976
41. LEVINE SD, WEBER H, SCHLONDORFF D: Inhibitin of adenylate
cyclase by general anesthetics in toad urinary bladder. Am J
Physiol 237:F372—F378, 1979
42. HANDLERJS, BENSINGER R, ORLOFF J: Effect of adrenergic agents
on toad bladder response to ADH, 3' 5'-AMP, and theophylline.
Am J Physiol 215:1024—1031, 1968
43. BERL T: Cellular calcium uptake in the action of prostaglandins on
renal water excretion. Kidney mt 19:15—23, 1981
44. WOLFF Di, BROSTROM CO: Properties and functions of the
calcium—dependent regulator protein. Adv Cyclic Nucleotide Res
11:27—88, 1979
45. VOLPI M, SHA'AFI RI, EPSTEIN PM, ANDRENYAK DM, FEINSTEIN
MB: Local anesthetics, mepacrine, and propranolol are antagonists
of calmodulin. Proc Nail Acad Sd USA 78:795—799, 1981
46. EPSTEIN PM, FISS K, HACHISU R, ANDRENYAK DM: Interaction of
calcium antagonists with cyclic AMP phosphodiesterases with
calmodulin. Biochem Biophys Res Corn 105:1142—1149, 1982
47. PIASCIK MT, WISLER PL, JOHNSON CL, POTTER JD: Ca2-depe-
ndent regulation of guinea pig brain adenylate cyclase. J Biol Chern
255:4176—4181, 1980
48. AUSIELLO DA, KREISBERG ii, Roy C, KARNOVSKY Mi: Contrac-
tion of cultured rate glomerular cells of apparent mesangial origin
after stimulation with angiotensin II and arginine vasopressin. J
C/in Invest 65:754—760, 1980
49. SCHARSCHMIDT LA, DUNN Mi: Prostaglandin synthesis by rat
glomerular mesangial cells in culture. J C/in Invest 71:1756—1764,
1983
50. SWIDLER M, BONVENTRE JV: Calcium dependency of
prostaglandin E2 (PGE2) production in cultured mesangial cells.
C/in Res (abstract) 34:611, 1986
51. BRENNER BM, DWORKIN LD, IcHIKAwA I: Glomerular ultrafiltra-
tion, in The Kidney, edited by BRENNER BM, RECTOR FC JR., New
York, Saunders, pp. 124—144, 1986
52. TROYER DA, KREISBERG ii, SCHWERTZ DW, VENKATACHALAM
MA: Effects of vasopressin on phosphoinositides and prostaglandin
production in cultured glomerular mesangial cells. Am J Physiol
249:Fl39—F147, 1985
53. BONVENTRE JV, SKORECKI KL, KREISBERG JI, CHEUNG JY: Vaso-
pressin increases cytosolic free calcium concentration in glomeru-
lar mesangial cells. Am J Physiol 251 :F94—F102, 1986
54. Woos NM, CUTHBERTSON KSR, COBBOLD PH: Repetitive tran-
sient rises in cytosolic free calcium in hormone—stimulated
hepatocytes. Nature 319:600—602, 1986
55. WILLIAMSON JR, COOPER RH, JOSEPH SK, THOMAS AP: Inositol
trisphosphate and diacylglycerol as intracellular second messengers
in liver. Am J Physiol 248:C203—C216, 1985
56. NABIKA T, VELLETRI PA, LOVENBERG W, BEAVEN MA: Increase
in cytosolic calcium and phosphoinositide metabolism induced by
angiotensin II and [Argi vasopressin in vascular smooth muscle
cells. J Biol Chem 260:4661—4670, 1985
57. SIESS W, STIFEL M, BINDER H, WEBER PC: Activation of V1-
receptors by vasopressin stimulates inositol phospholipid hydroly-
sis and arachidonate metabolism in human platelets. Biochem J
233:83—91, 1986
58. MICHELL B: Profusion and confusion, Nature 319:176—177, 1986
59. WILSON DB, BRoss TE, SHERMAN WR, BERGER RA, MAGERUS
PW: Inositol cyclic phosphates are produced by cleavage of
phosphatidylphosphoinositols (polyphosphoinositides) with puri-
fied sheep seminal vesicle phospholipase C enzymes. Proc Nail
Acad Sci USA 82:4013—4017, 1985
60. SCHLONDORFF D, PEREZ J, SATRIANO JA: Differential stimulation
of PGE2 synthesis in mesangial cells by angiotensin and A23l87.
Am J Physiol 248:Cl 19—C 126, 1985
61. VENKATACHALAM MA, KREISBERG JI: Agonist—induced isotonic
contraction of cultured mesangial cells after multiple passages. Am
J Physiol 249:C48—C55, 1985
62. ZU5MAN RM, KEISER HR: Prostaglandin biosynthesis by rabbit
renomedullary interstitial cells in tissue culture. Stimulation by
angiotensin II, bradykinin and arginine vasopressin. J C/in Invest
60:215—223, 1977
63. SCHLONDORFF D, SATRIANO JA, SCHWARTZ GJ: Synthesis of
prostaglandin E2 in different segments of isolated collecting tubules
from adult and neonatal rabbits. Am J Physiol 248:F134—F144, 1985
64. GRENIER FC, ROLLINS, TE, SMITH WL: Kinin—induced pros-
taglandin synthesis by renal papillary collecting tubule cells in
culture. Am J Physiol 241:F94—Fl04, 1981
65. ZUSMAN RM, KEISER HR: Prostaglandin E2 biosynthesis by rabbit
renomedullary interstitial cells in tissue culture. J Biol Chem
252:2069-2071, 1977
66. BECK TR, HASSID H, DUNN Mi: The effect of arginine vasopressin
and its analogues on the synthesis of prostaglandin E2 by rat renal
medullary interstitial cells in culture. J Pharmacol Exp Ther 215:
15—19, 1980
67. AUSIELLO DA, ZUSMAN RM: The role of calcium in the stimulation
of prostaglandin synthesis by vasopressin in rabbit renal medullary
interstitial cells in tissue culture. Biochem J 220:139—145, 1984
68. CRAVEN PA, DERUBERTIS FR: Calcium dependence of the stimula-
tory action of hypertonicity on renal medullary prostaglandin
synthesis. Biochim Biophys Acta 804:450—458, 1984
69. ZENSER TV, DAVIS BB: Effects of calcium and A23l87 on renal
inner medullary prostaglandin E2 synthesis. Am J Physiol 238:
E371—E376, 1980
70. CRAVEN PA, STUDER RK, DERUBERTIS FR: Renal inner medullary
prostaglandin synthesis. A calcium—calmodulin—dependent process
suppressed by urea. J C/in Invest 68:722—732, 1981
71. CRAVEN PA, DERUBERTIS FR: Ca2-calmodulin dependent release
of arachidonic acid for renal medullary prostaglandin synthesis:
Evidence for involvement of phospholipases A2 and C. JBiol Chem
258:4814—4823, 1983
72. CRAVEN PA, DERUBERTIS FR: Effects of vasopressin and urea on
Ca2-calmodulin--dependent renal prostaglandin E. Am J Physiol
24l:F649—F658, 1981
73. STOKES JB, KOKKO JP: Inhibition of sodium transport by
prostaglandin E2 across the isolated perfused rabbit collecting
tubule. J C/in Invest 59:1099—1104, 1977
74. TORIKAI S, KUROKAWA K: Effect of PGE2 on vasopressin—depend-
ent cell cAMP in isolated single nephron segments. Am J Physiol
245:F58—F66, 1983
75. STOKES JB: Effect of prostaglandin E2 on chloride transport across
the rabbit thick ascending limb of Henle. J C/in Invest 64:495—502,
1979
76. STOFF JS, ROSA RM, SILVA P. EPSTEIN FH: Indomethacin impairs
water diuresis in the DI rat: Role of prostaglandins independent of
ADH. Am J Physiol 241:F23l—F237, 1981
77. BURCH RM, HALUSHKA PV: Thromboxane and stable prosta-
glandin endoperoxide analogs stimulate water permeability in the
toad urinary bladder. J C/in Invest 66:1251—1257, 1980
78. GANGULI M, TOBIAN L, AZAR S, O'DONNELL M: Evidence that
prostaglandin synthesis inhibitors increase the concentration of
sodium and chloride in rat renal medulla. Circ Res 40:1135—1139,
1977
